Mahmoud A E, Elias E, Beauchamp N, Wilde J T
Liver & Hepatobiliary Unit, Queen Elizabeth Hospital, Edgbaston, Birmingham.
Gut. 1997 Jun;40(6):798-800. doi: 10.1136/gut.40.6.798.
The factor V Leiden (FVL) mutation has been shown to be the most frequent cause of hereditary thrombophilia. The prevalence of the mutation in patients with Budd-Chiari syndrome (BCS) and portal vein thrombosis (PVT) has not been fully elucidated.
To investigate the association between the FVL mutation and BCS and PVT.
Thirty patients with BCS, 32 patients with PVT, and a control group of 54 patients with liver disorders and no history of thrombosis.
The factor V gene was analysed for the presence of the FVL mutation by a polymerase chain reaction (PCR) technique. The presence of the mutation was confirmed by DNA sequencing.
Seven (23%) patients with BCS, one (3%) patient with PVT, and three (6%) patients in the control group were identified as having the FVL mutation. There of the BCS patients had coexisting hypercoagulable states. The prevalence of the FVL mutation was significantly higher in patients with BCS compared with patients with PVT and controls (p < 0.04). The FVL mutation was the second most common aetiology associated with BCS.
The FVL mutation is an important factor in the pathogenesis of BCS and screening for the disorder must be included in the investigation of patients presenting with this condition. In contrast, the FVL mutation is not a major predisposing factor in the pathogenesis of PVT.
已证实因子V莱顿(FVL)突变是遗传性血栓形成倾向最常见的原因。布加综合征(BCS)和门静脉血栓形成(PVT)患者中该突变的患病率尚未完全阐明。
研究FVL突变与BCS和PVT之间的关联。
30例BCS患者、32例PVT患者以及54例有肝脏疾病且无血栓形成病史的对照组患者。
采用聚合酶链反应(PCR)技术分析因子V基因是否存在FVL突变。通过DNA测序确认突变的存在。
7例(23%)BCS患者、1例(3%)PVT患者和3例(6%)对照组患者被确定存在FVL突变。其中部分BCS患者存在并存的高凝状态。与PVT患者和对照组相比,BCS患者中FVL突变的患病率显著更高(p < 0.04)。FVL突变是与BCS相关的第二常见病因。
FVL突变是BCS发病机制中的一个重要因素,对于出现这种情况的患者进行调查时必须包括对该疾病的筛查。相比之下,FVL突变不是PVT发病机制中的主要诱发因素。